I. Jiangsu Ruijing Technology Development Co., Ltd.: National policies will further promote industrial upgrading. With the issuance of Document No. 44 [2015] by the State Council, “Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices,” the state has further encouraged innovation in medical device research and development. Applications for registration of innovative medical devices that possess core technology invention patents and demonstrate significant clinical value are now included in the scope of special review and approval procedures and will be processed with priority. The government is also promptly revising medical device standards, increasing the adoption rate of international standards, and enhancing the quality of domestically produced medical devices. These policy signals undoubtedly represent a major positive factor for the development of our medical device industry, while medical device technology itself stands out as a promising new growth area with considerable potential for industrialization. Seizing this opportunity, Jiangsu Ruijing Technology Development Co., Ltd. has embraced the trend of industrial upgrading, using new product R&D and technological innovation as entry points to embark on a path of sustainable corporate development—“quality first, innovation-driven, endogenous growth.” II. Jiangsu Ruijing Technology Development Co., Ltd.: Innovation is an indispensable pathway for upgrading the medical device industry. Traditional economics typically employs static analytical methods, categorizing production factors into three types: land, labor, and capital. However, with continuous advances in science and technology, the concept of production factors has evolved into a dynamic one, profoundly altering both its connotation and extension. In terms of extension, it encompasses not only tangible assets such as machinery, equipment, and factory buildings, but also intangible elements like trademarks, brands, and innovative capabilities; it includes both naturally endowed resources like land and other natural assets, as well as human‑created factors such as technology and management; moreover, it covers not only low‑value‑added inputs like ordinary resources, but also high‑value‑added components such as highly trained professionals. From the perspective of Jiangsu Ruijing Technology Development Co., Ltd.’s management, upgrading the medical device industry essentially means upgrading these production factors—especially those developed through human effort, namely technological innovation. A representative from Jiangsu Ruijing Technology Development Co., Ltd. stated: “Over more than a decade of development, we have consistently prioritized collaboration with domestic universities, research institutes, and other scientific institutions. We now offer two major product lines—anesthesia consumables and nursing consumables. Nevertheless, we firmly believe that innovation is one of the most reliable pathways for upgrading China’s medical device industry. Therefore, over the past two years, we have vigorously strengthened technological innovation, accumulating a portfolio of core technologies that will serve as a crucial cornerstone for driving our company’s sustainable growth in the years ahead.” III. Jiangsu Ruijing Technology Development Co., Ltd. focuses on the “seven‑inch” segment of the medical device industry. The “seven‑inch” refers to a critical link within the industrial chain characterized by high technological content and added value, occupying a pivotal position in determining overall industry competitiveness. Within the medical device supply chain, innovation occupies this key “seven‑inch” position, playing an especially vital role in advancing China’s medical device sector. A hallmark of this “seven‑inch” segment is its high level of technological sophistication, its strategic importance in the chain, and its capacity to drive broader industrial upgrades—insights that hold valuable lessons for the development of China’s medical device industry. Indeed, the advancement of this sector must be underpinned by cutting‑edge innovation. Furthermore, as China transitions from traditional industrialization toward a new type of industrialization, there is an objective imperative for upgrading the medical device industry. This so‑called “new industrialization” emphasizes leveraging information technology to propel industrialization, while simultaneously using industrialization to advance information technology—resulting in an industrial model marked by high technological content, strong economic returns, reduced resource consumption, minimal environmental pollution, and the full utilization of human resource advantages. In response, a spokesperson for Jiangsu Ruijing Technology Development Co., Ltd. remarked: “Innovation is a critical component of the medical device supply chain that places high demands on companies’ technological capabilities. Consequently, upgrading human resources—enhancing the skills and qualifications of workers—has become one of the central tasks in today’s human resource management for medical device manufacturers. Similarly, just as human resource upgrading is essential, efforts related to brand management, corporate innovation capacity, corporate culture, R&D in medical device manufacturing technologies, and enterprise management—all will undergo corresponding upgrades driven by the foundational need to move toward innovation. Ultimately, this holistic approach will lead to comprehensive industrial upgrading. In other words, seizing this ‘seven‑inch’ opportunity paves the way toward achieving the ultimate goal of full‑scale industrial transformation.” IV. Jiangsu Ruijing Technology Development Co., Ltd.: Strengthening the foundation of quality, bolstering independent innovation, and pursuing endogenous growth. “Quality first, innovation driven, endogenous growth” has long been the guiding principle upheld by Jiangsu Ruijing Technology Development Co., Ltd. The company strives to anticipate emerging trends in the next wave of industrial upgrading within the medical device sector, focusing on enhancing original innovation capabilities, conducting R&D on cutting‑edge, foundational, and core technologies, and securing technological leadership. By adopting a differentiated innovation strategy—specialized, refined, distinctive, and novel—the company leverages support from leading research institutions, actively developing new products and applying advanced technologies, while simultaneously building up reserves of sophisticated technologies and intelligent information systems. It also undertakes the transformation of traditional medical device products, integrating these innovations seamlessly into the broader industrial upgrade process. At the same time, the company places particular emphasis on elevating worker qualifications, innovating talent‑management concepts, accelerating the development of an innovative team of technologists, a high‑caliber management cadre, and a workforce of highly skilled employees, thereby propelling the enterprise toward becoming knowledge‑intensive, innovation‑driven, and endogenously growing. Industry experts point out that the medical device sector is currently at a critical juncture, poised for a qualitative leap. The core challenge in transitioning from size to strength lies in strengthening corporate R&D capabilities and developing innovative technological products—adjusting industrial structures accordingly, transforming development models, and setting the stage for the industry to enter a phase of rapid, sustained growth. Jiangsu Ruijing Technology Development Co., Ltd. is expected to emerge as a quintessential exemplar of technological innovation within the industry, representing—in many ways—a meaningful and valuable contribution from large enterprises in the medical device field. We are confident that the company’s development philosophy of “quality first, innovation driven, endogenous growth” will serve as a vital cornerstone for ensuring its continued, stable progress. Jiangsu Ruijing Technology: Quality First, Innovation Driven, Endogenous Growth.